Johnston Anna, Salles Gilles
Service d'Hématologie, Hospices Civils de Lyon, 69495 Pierre Benite, Lyon, France.
Hematol Oncol Clin North Am. 2008 Oct;22(5):839-61, viii. doi: 10.1016/j.hoc.2008.07.012.
The prognostication of lymphoma patients remains important to optimize treatments choices. Clinically based indices, such as the International Prognosis Index and the Follicular Lymphoma International Prognosis Index, developed respectively for aggressive and follicular lymphoma, are of great value in routine practice and clinical research, but they reflect only the biologic heterogeneity of these diseases. New techniques have made it possible to unravel the underlying biologic pathways associated with outcome. The current challenge, translating these molecular findings into clinical practice, requires the validation of those biomarkers in large cohorts of patients.
淋巴瘤患者的预后评估对于优化治疗选择仍然至关重要。基于临床的指标，如分别为侵袭性淋巴瘤和滤泡性淋巴瘤制定的国际预后指数和滤泡性淋巴瘤国际预后指数，在常规实践和临床研究中具有重要价值，但它们仅反映了这些疾病的生物学异质性。新技术使得揭示与预后相关的潜在生物学途径成为可能。当前的挑战是将这些分子研究结果转化为临床实践，这需要在大量患者队列中验证这些生物标志物。
